AIM vs. CRON, TEV, SLS, ABT, NOT, PYR, NVO, DNA, TLRY, and VBV
Should you be buying Aimia stock or one of its competitors? The main competitors of Aimia include Cronos Group (CRON), Tervita (TEV), Solaris Resources (SLS), Absolute Software Co. (ABT.TO) (ABT), Noront Resources (NOT), PyroGenesis Canada Inc. (PYR.V) (PYR), Novo Resources Corp. (NVO.V) (NVO), Dalradian Resources (DNA), Tilray Brands (TLRY), and VBI Vaccines (VBV). These companies are all part of the "pharmaceutical products" industry.
Aimia vs.
Cronos Group (TSE:CRON) and Aimia (TSE:AIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership, community ranking and earnings.
In the previous week, Aimia had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Aimia and 0 mentions for Cronos Group. Aimia's average media sentiment score of 0.55 beat Cronos Group's score of 0.00 indicating that Aimia is being referred to more favorably in the news media.
Aimia has a net margin of -16.96% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -4.40% beat Aimia's return on equity.
Aimia received 321 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 54.24% of users gave Aimia an outperform vote while only 50.74% of users gave Cronos Group an outperform vote.
Cronos Group has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Aimia has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
16.0% of Cronos Group shares are held by institutional investors. Comparatively, 31.6% of Aimia shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Comparatively, 3.3% of Aimia shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cronos Group has higher earnings, but lower revenue than Aimia. Cronos Group is trading at a lower price-to-earnings ratio than Aimia, indicating that it is currently the more affordable of the two stocks.
Aimia has a consensus target price of C$4.00, suggesting a potential upside of 45.99%. Given Aimia's stronger consensus rating and higher probable upside, analysts plainly believe Aimia is more favorable than Cronos Group.
Summary
Aimia beats Cronos Group on 11 of the 18 factors compared between the two stocks.
Get Aimia News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (TSE:AIM) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy AIM Stock Free AIM Stock Alerts